Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Neuroendocrine Tumors 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 24Cyclophosphamide 20fludarabine phosphate 16Mycophenolic Acid 13Filgrastim 12Cyclosporine 12Bortezomib 12Antilymphocyte Serum 11Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Lenalidomide 9fludarabine 8Radiotherapy 7Methotrexate 7Cord Blood Stem Cell Transplantation 7Melphalan 6Busulfan 6venetoclax 5Etoposide 5tanespimycin 4ibrutinib 4Polymerase Chain Reaction 4Methylprednisolone 4Granulocyte Colony-Stimulating Factor 4Flow Cytometry 4ublituximab 3thymoglobulin 3sargramostim 3carfilzomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Mantle-Cell × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT02488512 2018-03-19

itTRIOlym

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated
1 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡